Navigation Links
LigoCyte Pharmaceuticals Presents Data Showing Heterosubtypic,Protection Against Influenza Challenge With Virus-Like Particle,Immunization

BOZEMAN, Mont., May 01, 2007 /PRNewswire/ -- LigoCyte Pharmaceuticals presented preclinical data today showing that immunization with their influenza virus-like particles (VLPs) induced heterosubtypic protection in a virus challenge study. The company's data were presented by Dr. Joel Haynes, LigoCyte's senior director of vaccine development, at the Tenth Annual Conference on Vaccine Research sponsored by the National Foundation of Infectious Diseases in Baltimore.

The current influenza vaccination strategy involves immunization against hemagglutinin antigens that undergo continuous alteration in circulating influenza virus. Because the annual vaccines have to be manufactured in advance of influenza outbreaks, the unexpected emergence of a new or drifted subtype may result in a substantial reduction in protection.

LigoCyte's data show that immunization with their unique influenza H1N1-VLP formulation resulted in 100% protection against both H1N1 and H3N2 influenza challenge in preclinical studies. LigoCyte has also produced influenza VLPs carrying H3N2 and H5N1 antigens. H5N1 is the avian flu subtype that is currently circulating in bird populations and causing sporadic infections and death in humans.

"There is a great need for a universal influenza vaccine that simplifies manufacturing and delivery while enhancing protection against multiple viral subtypes," said Dr. Robert Bargatze, LigoCyte's chief scientific officer.

About LigoCyte:

LigoCyte, established in 1998, is developing a new generation of vaccines and monoclonal antibody therapeutics for the prevention and treatment of infectious diseases and inflammation. The company's investigational Norovirus vaccine for the prevention of acute gastroenteritis is currently in Phase I clinical studies. LigoCyte is advancing its other proprietary products into human clinical testing, positioning the company for continued growth an
'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/4/2009)OMAHA, Neb., Dec. 4 Amber Pharmacy announced today that it received accreditation by the Accreditation Commission for Health Care, Inc. (ACHC) for specialized pharmacy services. For nearly 15 years,
(Date:12/4/2009)SALT LAKE CITY, Dec. 4 Dynatronics Corporation (Nasdaq: DYNT ) announced it has signed a sole-source vendor agreement to provide therapy equipment and rehab supplies to Benchmark Physical Therapy wi
(Date:12/4/2009)WASHINGTON, Dec. 4 Chemistry World recently highlighted a new report published by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) that identifies 97 new drugs and vaccines in
Breaking Medicine Technology:Amber Pharmacy Earns Accreditation From ACHC 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2Worries May Worsen Peripheral Arterial Disease 54672 1Worries May Worsen Peripheral Arterial Disease 54672 2Pitt researchers harness carbon nanomaterials for drug delivery systems oxygen sensors 54668 1Pitt researchers harness carbon nanomaterials for drug delivery systems oxygen sensors 54668 2Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 1Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 2Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 3
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)Working with mice, scientists at Johns Hopkins publishing in the December issue of Neoplasia have shown that a protein made by a gene called "Twist" may be the proverbial red flag that can accuratel
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
(Date:12/4/2009)Dental tourism is a phenomenon that was started by people that were looking for an alternative to the high price of dental work in the US, Canada, and other countries. In their search for lower priced
Breaking Medicine News(10 mins):Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 2Health News:Mexican Dental Vacation Sees a Rush Of New Patients: Recession A Factor 3
...e smoking there is probably misuse of alcohol too,...esearchers in the Archives// of Internal Medicine.... used as a clinical indicator for alcohol misuse, ... although brief screening and brief intervention p...
...umer interests and those of the pharmaceutical ind... Senate Committee approved// a bill that would clo...cessary powers to require drug makers to wait two ...il to do post-approval studies and to ban advertis...
...he flu is nothing to be sneezed at//. The res...iversity of Texas-Houston, showed that about 90, 0...he U.S alone. The researchers say that this i... heart disease should never forgo their medication...
...h Haikerwal, said today that war veterans would ha...vices from 1 May following// the introduction of i... Officer (LMO) scheme for veterans’ health care. ... In practical terms, this means that patients ...
...ted that only a small percentage of food imported ...her, the 1.3% that is inspected// reveal contamina...he rest of the food that escapes inspection? ...to lenient food laws in the countries from where t...
...argest collections of liver tissue samples ever ac...System researchers have embarked on a massive stud... Nonalcoholic fatty liver disease starts with t...potentially fatal cirrhosis. If the damage becomes...
Other Medicine News:Health News:Smoking Indicator of Alcohol Misuse 2Health News:Moratorium Proposed on Advertisements of Newly Approved Drugs 2Health News:The Flu- More Than Just That 2Health News:Geisinger Launches Extensive Study on Obesity and Related Liver Problem 2
Insulin Autoantibody (IAA)
Benchtop Laminar Hood (Universal Hood)
Remote Blower With Bag-In/Bag-Out Option
Class II Type B2 Biological Safety Cabinet
Medicine Products: